Source: Cellular Biomedicine Group
Cellular Biomedicine Group Inc. (NASDAQ:CBMG)
(CBMG or the Company), a leading clinical-stage biopharmaceutical firm
engaged in the development of immunotherapies for cancer and stem cell
therapies for degenerative diseases and GE Healthcare Life Sciences
China, today announced that they have established a strategic research
collaboration to co-develop certain high-quality industrial control
processes in Chimeric Antigen Receptor T-cell (CAR-T) and stem cell
manufacturing. In connection with the collaboration, a joint laboratory
within CBMG’s new Shanghai Zhangjiang GMP-facility will be established
and dedicated to the joint research and development of a functionally
integrated and automated immunotherapy cell preparation system.
Cellular Biomedicine Group (CBMG) and GE Healthcare Life Sciences China
Tony Liu, CEO of CBMG (seated, left) and Angela Chen of GE Healthcare Life Sciences China (seated, right) sign agreement to establish strategic research collaboration.
Cellular Biomedicine Group Inc.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/ab5bc905-b526-4e86-98bd-c96e306b5796
CBMG
and GE Healthcare Life Sciences China plan to develop state-of-the-art
automated CAR-T and stem cell manufacturing capabilities that build upon
the accreditation of CBMG’s GMP facilities in Shanghai, Wuxi and
Beijing. The co-development activity will aim to standardize the
delivery of cell manufacturing to potentially improve throughput,
alleviate cost burdens and to minimize variability in cell production,
which may increase the availability of engineered cells upon
commercialization.
This partnership combines
CBMG’s scientific expertise in the manufacturing of CAR-T and stem cell
production in China and GE Healthcare’s renowned expertise in the design
and development of innovative manufacturing technologies for the
biopharmaceutical industry.
Recently, CBMG
announced that its new Zhangjiang facility, together with an expanded
Wuxi, and Beijing GMP-facilities, will have a combined 70,000 square
feet for development and production. This will enable CBMG to conduct
simultaneous clinical trials for multiple CAR-T and stem cell product
candidates. At full production volumes, these facilities could support
the treatment of up to 10,000 cancer patients and 10,000 knee
osteoarthritis patients per year.
“GE
Healthcare‘s selection of our facility to serve as their showcase site
in China, credits our GMP stature and capabilities. Our team of
scientists has spent years refining our manufacturing process to become
one of the very few cell therapy companies with fully in-house
integrated chemistry, manufacturing, and controls (CMC) processes for
clinical grade CAR-T cells, plasmid and viral vectors bank production.
We understand that one of the impending barriers to adoption of
immuno-oncology and stem cell therapies is the logistics in
manufacturing and we look to take an expanded role both domestically and
potentially globally. We are pleased to be in a strategic partnership
with GE Healthcare and look forward to showcasing our facilities and the
mutual benefit this joint laboratory will bring,” commented Tony Liu,
Chief Executive Officer, CBMG.
“Cell therapy as an
industry continues to refine and evolve in China with vast potential to
change the ways various diseases are treated. GE continues investing
in technologies and services aimed at the thriving cell therapy industry
with a firm commitment of making these promising therapies accessible
through successful industrialization. We are pleased to partner with
CBMG, a leader in CAR-T and stem cell development in China and to take
advantage of their excellent CMC cell production capabilities.
Collaboration with ambitious partners like CBMG who share our vision is
necessary for advancing innovation and delivering comprehensive
manufacturing solutions for cell and regenerative medicines,” said Li
Qing, General Manager, GE Healthcare Life Sciences, Greater China.
Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) develops proprietary cell therapies for the treatment of cancer and degenerative diseases. We conduct immuno-oncology and stem cell clinical trials in China using products from our integrated GMP laboratory. Our GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards. CBMG recently commenced two Phase I human clinical trials in China using CAR-T to treat relapsed/refractory CD19+ B-cell Acute Lymphoblastic Leukemia (ALL) and Refractory Diffuse Large B-cell Lymphoma (DLBCL) as well as an ongoing Phase I trial in China for AlloJoinTM (CBMG’s “Off-the-Shelf” Allogeneic Human Adipose-derived Mesenchymal Stem Cell) for the treatment of Knee Osteoarthritis (KOA). CBMG was also recently awarded $2.29 million from the California Institute for Regenerative Medicine (CIRM) to support pre-clinical studies of AlloJoinTM for Knee Osteoarthritis in the United States. To learn more about CBMG, please visit www.cellbiomedgroup.com.
About GE Healthcare
GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE:GE) works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients. For more information about GE Healthcare, visit our website at www.gehealthcare.com.
No comments:
Post a Comment